This content is first seen at Medscape Medical News.
Citation: Head-to-Head Comparison of 25 Migraine Meds Reveals Top Options – Medscape – May 02, 2023.
Disclaimer: The information provided in this site is correct at the time of publication. POMConnect assumes no responsibility or liability for any errors or omissions in the content of this site.
A recent analysis of data from over 3 million migraine attacks reveals that triptans, ergots, and antiemetics are the most effective classes of medications for relieving migraine headaches.
The study, presented at the American Academy of Neurology’s 2023 Annual Meeting, aligns with clinical trial results and treatment guidelines, providing valuable insights to complement clinical practice.
Dr. Chia-Chun Chiang, a neurologist at Mayo Clinic, Rochester, Minnesota, stated that this research is the first to simultaneously compare various acute migraine medications using a Big Data approach based on real-world patient-provided data.
Dr Chia-Chun Chiang
The researchers collected over 10 million self-reported migraine attack records from a migraine smartphone app called Migraine Buddy, which allowed users to report the effectiveness of treatments. They analyzed 25 acute medications from seven classes and employed a statistical model to assess treatment effectiveness by adjusting for concurrent medications and user-specific factors.
Among the medications studied, triptans, ergots, and antiemetics demonstrated the highest efficacy, followed by opioids, NSAIDs, combination analgesics, others, and acetaminophen. Specific medications with the greatest patient-reported effectiveness were eletriptan, zolmitriptan, and sumatriptan.
This patient-reported comparative effectiveness analysis supports existing treatment recommendations and highlights the importance of triptans in migraine management. The research showcases the potential of Big Data analysis and smartphone-collected real-world data to guide more personalized and effective healthcare approaches.
In response to this research, Shaheen Lakhan, MD, PhD, a neurologist and researcher in Boston, commented to Medscape Medical News, stating, “This study showcases the significant potential of Big Data, demonstrating the capacity of smartphones to gather real-world data, and the expertise of researchers, such as those at Mayo Clinic, in analyzing them.”
Lakhan noted, “The study provides insights into comparing different treatments. I anticipate the next phase of this research could involve determining the effectiveness of specific medications for distinct migraine populations and even on an individual level.”
He emphasized that as these models are developed, the era of trial-and-error medicine could be replaced with personalized healthcare.
Link to the full News (Medscape Medical News):
https://www.medscape.com/viewarticle/991450?ecd=wnl_dne5_230502_MSCPEDIT&uac=123878HG&impID=5392756
